Janux Therapeutics, Inc.

Janux does not sell approved products to end patients; its current business is built around advancing drug candidates and partnering with large pharmaceutical and biotechnology companies. Its direct counterparties are clinical trial sites, regulators, and collaboration partners such as Merck, while the eventual customers for any approved therapy would be oncologists, hospitals, and cancer centers treating patients with solid tumors or hematologic cancers. The company’s commercial opportunity depends on proving that its tumor-activated biology can deliver a better safety profile and efficacy than competing immuno-oncology approaches.

Janux’s strategy is to advance its tumor-activated immunotherapy platforms into the clinic and demonstrate a safety and efficacy profile that can compete with existing T-cell engagers and other oncology modalities. Near term, the company is prioritizing JANX007 and JANX008, while preserving optionality through preclinical programs, intellectual property, and collaboration opportunities. Capital discipline is important because the business remains pre-revenue and depends on external financing and/or partnership economics to fund development.